ABHD5 and cancer: Using SR-3420, a highly selective synthetic agonist for ABHD5-mediated lipolysis (20, 21), we demonstrated that pharmacological activation of ABHD5 potently inhibits mTORC1, the master signaling driver for cancer cell anabolism.